In short
Currently, there is 1 ongoing clinical trial investigating treatments for Latent Autoimmune Diabetes In Adults (LADA), a form of diabetes that shares characteristics with both Type 1 and Type 2 diabetes. This trial is examining the long-term effects of GAD-alum treatment on insulin production and diabetes control in adults with this condition.
Clinical trial locations
- Norway
- Sweden
Study on Latent Autoimmune Diabetes in Adults (LADA) Patients: Evaluating Diabetes Status 3 Years After Treatment with Glutamate Decarboxylase 2
This clinical trial is being conducted in Sweden and Norway and focuses on understanding the long-term effects of a treatment called GAD-alum in people with Latent Autoimmune Diabetes in Adults. LADA is a unique form of diabetes that develops in adults and involves the gradual loss of the body's ability to produce insulin due to an autoimmune process.
Who can participate:
- You must have previously participated in a related study called GADinLADA
- You need to sign an informed consent form, showing you understand and agree to take part in the study
- Both men and women are eligible to participate
- You must have LADA, not other types of diabetes
Who cannot participate:
- People with other types of diabetes besides LADA
- Those who did not participate in the previous GADinLADA study
- Individuals outside the specified age range for the study
- People who do not carry a specific genetic marker called HLA-DR3DQ2, which is related to the immune system
- Members of vulnerable populations who may need special protection
What the trial focuses on:
The main goal of this study is to examine whether GAD-alum treatment has lasting benefits three years after it was first given. Researchers want to understand if this treatment can help preserve the body's ability to produce insulin and maintain better blood sugar control over time. They are particularly interested in comparing results between people who carry the HLA-DR3DQ2 genetic marker and those who do not.
The investigational treatment:
The treatment being studied is GAD-alum, also known as Diamyd. This is an injection containing glutamate decarboxylase 2, a protein that works with the immune system. The treatment is injected directly into the lymph nodes, a technique called intralymphatic administration. GAD-alum is designed to reduce the autoimmune attack on the insulin-producing cells in the pancreas, potentially helping to preserve their function and slow the progression of diabetes.
Participants will undergo assessments to measure their diabetes status, including how well their bodies produce insulin and control blood sugar levels. The study is expected to conclude by March 31, 2025, and will provide valuable information about whether this immunomodulatory approach offers long-term benefits for people living with LADA.
Summary
Currently, only one clinical trial is actively recruiting for Latent Autoimmune Diabetes in Adults. This trial is a follow-up study taking place in two Scandinavian countries: Sweden and Norway. The focus is exclusively on the investigational drug GAD-alum, which aims to modulate the immune system and preserve the insulin-producing capacity in people with this condition.
What makes this trial unique is that it only accepts participants who were previously enrolled in an earlier study, making it a long-term follow-up investigation. The trial also focuses on a specific genetic marker, HLA-DR3DQ2, to better understand which patients may benefit most from this type of treatment. This approach reflects a growing interest in personalized medicine for autoimmune forms of diabetes.
If you have LADA and participated in the previous GADinLADA study, this trial may offer an opportunity to contribute to research that could improve treatment options for others with this condition in the future.
